NASDAQ:CGEN
Compugen Ltd. Stock News
$1.99
+0.0600 (+3.11%)
At Close: May 01, 2024
Why Compugen Stock Is Jumping Today
11:40am, Thursday, 13'th May 2021
Investors liked what the company had to say in its Q1 update.
Compugen Reports First Quarter 2021 Results
07:00am, Thursday, 13'th May 2021
HOLON, Israel, May 13, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results
Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series
07:00am, Tuesday, 11'th May 2021
HOLON, Israel, May 11, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Eran Ophir, Ph
HOLON, Israel, May 10, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expa
Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021
07:00am, Monday, 03'rd May 2021
HOLON, Israel, May 3, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company wi
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting
07:00am, Thursday, 29'th Apr 2021
HOLON, Israel, April 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will pr
Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy
07:00am, Tuesday, 27'th Apr 2021
HOLON, Israel, April 27, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication
7 Stocks That Could Double by Summer
02:29pm, Monday, 05'th Apr 2021
These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first
ARK Invest: Illiquid Positions Threaten to Drown Bubbly ETFs
02:24pm, Thursday, 04'th Mar 2021
Catherine Wood has plunged deeper into illiquid stocks in an effort to prop up faltering positions
Compugen: Serious Partnerships, Tremendous Potential, But Several Years To Wait
06:55am, Sunday, 28'th Feb 2021
Compugen is an early-stage biotechnology company developing cancer immunotherapies from predictive computational discovery platforms. Compugen has an early-stage pipeline of three computationally-disc
ARK Invest: Danger Looms as High-Flying ETFs Falter
11:06am, Friday, 26'th Feb 2021
ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2020 Results - Earnings Call Transcript
05:50pm, Thursday, 25'th Feb 2021
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2020 Results - Earnings Call Transcript
Compugen Reports Fourth Quarter and Full Year 2020 Results
07:05am, Thursday, 25'th Feb 2021
HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results f
Compugen To Test COM701, Opdivo Combination In Solid Tumor Settings
01:58pm, Monday, 22'nd Feb 2021
Compugen Ltd (NASDAQ: CGEN) expands its clinical collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY), wherein Bristol Myers will supply Opdivo (nivolumab) for Compugen's Phase 1b c
HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its
